Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 11:53AM ET
25.47
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-2.21 Insider Own37.68% Shs Outstand80.50M Perf Week0.12%
Market Cap2.20B Forward P/E- EPS next Y-1.55 Insider Trans-0.23% Shs Float53.90M Perf Month74.69%
Income-190.42M PEG- EPS next Q-0.53 Inst Own62.01% Short Float10.85% Perf Quarter65.39%
Sales174.91M P/S12.59 EPS this Y9.17% Inst Trans1.28% Short Ratio3.40 Perf Half Y109.46%
Book/sh3.85 P/B6.62 EPS next Y25.59% ROA-39.26% Short Interest5.85M Perf Year72.33%
Cash/sh3.15 P/C8.08 EPS next 5Y21.00% ROE-50.37% 52W Range9.90 - 25.55 Perf YTD57.90%
Dividend Est.- P/FCF- EPS past 5Y4.07% ROI-56.42% 52W High-0.31% Beta0.18
Dividend TTM- Quick Ratio3.94 Sales past 5Y51.62% Gross Margin93.26% 52W Low157.27% ATR (14)0.46
Dividend Ex-Date- Current Ratio4.19 EPS Y/Y TTM5.92% Oper. Margin-118.09% RSI (14)86.00 Volatility0.15% 1.28%
Employees355 Debt/Eq0.08 Sales Y/Y TTM26.51% Profit Margin-108.86% Recom2.78 Target Price26.30
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q14.02% Payout- Rel Volume0.33 Prev Close25.47
Sales Surprise5.14% EPS Surprise6.91% Sales Q/Q34.55% EarningsFeb 06 BMO Avg Volume1.72M Price25.47
SMA209.71% SMA5037.94% SMA20069.50% Trades Volume223,432 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Neutral $14
Oct-30-23Upgrade Piper Sandler Neutral → Overweight $23
Aug-10-23Upgrade Stifel Hold → Buy $14 → $20
Jan-04-23Upgrade Guggenheim Neutral → Buy $22
Aug-29-22Initiated Cowen Outperform $25
Aug-05-22Upgrade JMP Securities Mkt Perform → Mkt Outperform $23
Feb-28-22Downgrade Barclays Equal Weight → Underweight $11 → $6
Nov-08-21Downgrade Stifel Buy → Hold $60 → $10
Nov-08-21Downgrade Canaccord Genuity Buy → Hold $72 → $12
Nov-08-21Downgrade Barclays Overweight → Equal Weight $50 → $11
May-10-24 01:54PM
09:30AM
08:50AM
Apr-30-24 07:10AM
07:03AM
07:02AM Loading…
07:02AM
07:00AM
03:41AM
Apr-29-24 02:36PM
02:17PM
01:41PM
01:02PM
12:17PM
12:16PM
11:19AM
10:46AM Loading…
10:46AM
10:33AM
09:57AM
09:02AM
08:54AM
07:29AM
07:29AM
07:29AM
07:18AM
07:06AM
07:00AM
Apr-24-24 10:01AM
Apr-21-24 10:39AM
Apr-09-24 07:00AM
Mar-07-24 11:31AM
08:28PM Loading…
Mar-04-24 08:28PM
Feb-28-24 09:55AM
Feb-27-24 07:00AM
Feb-12-24 09:55AM
Feb-07-24 09:20AM
08:28AM
12:33AM
Feb-06-24 07:00AM
Feb-01-24 04:50PM
07:00AM
Jan-30-24 10:01AM
Jan-18-24 11:13AM
Jan-08-24 07:00AM
Jan-05-24 07:00AM
Jan-02-24 07:00AM
Dec-15-23 07:06AM
Dec-02-23 07:08AM
Nov-29-23 11:30AM
07:00AM
Nov-07-23 07:00AM
Nov-01-23 03:03AM
Oct-31-23 07:25AM
04:51AM
01:16AM
Oct-30-23 08:15AM
07:01AM
07:00AM
Oct-16-23 12:39PM
Oct-05-23 11:38AM
Sep-29-23 09:00AM
Sep-22-23 12:02PM
11:46AM
Sep-15-23 05:00PM
Sep-08-23 11:30AM
Aug-21-23 07:43PM
Aug-19-23 07:40AM
Aug-18-23 04:05PM
Aug-11-23 03:30PM
Aug-10-23 08:13AM
Aug-09-23 08:50AM
07:00AM
Aug-03-23 04:15PM
Aug-02-23 07:00AM
Jun-09-23 09:02AM
Jun-02-23 11:31AM
May-25-23 05:00PM
May-23-23 07:00AM
May-08-23 01:31PM
07:00AM
May-04-23 05:38AM
May-03-23 08:15AM
07:00AM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
07:00AM
Apr-19-23 07:00AM
Apr-18-23 06:53AM
Mar-23-23 11:30AM
Mar-16-23 05:25PM
Mar-15-23 11:52AM
06:28AM
Mar-14-23 05:53PM
05:32PM
04:26AM
Mar-09-23 11:30AM
Mar-01-23 07:00AM
Feb-27-23 07:00AM
Feb-08-23 02:13PM
08:43AM
05:40AM
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Thomas PatrickChief Financial OfficerFeb 16 '24Sale15.623,01047,00980,350Feb 20 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerFeb 16 '24Sale15.622,61540,840108,739Feb 20 04:06 PM
Pitman JamaSVP, Chief Development OfficerFeb 16 '24Sale15.622,26735,40568,031Feb 20 04:05 PM
Martin Daniel C.Chief Commercial OfficerFeb 16 '24Sale15.622,26735,40555,118Feb 20 04:05 PM
Kelly Thomas PatrickChief Financial OfficerJan 16 '24Sale14.472,43535,23466,085Jan 18 04:15 PM
Sherman Matthew LEVP & Chief Medical OfficerJan 16 '24Sale14.472,43535,23494,079Jan 18 04:15 PM
Pitman JamaSVP, Chief Development OfficerJan 16 '24Sale14.471,62423,49950,573Jan 18 04:15 PM
Martin Daniel C.Chief Commercial OfficerJan 16 '24Sale14.471,62423,49947,660Jan 18 04:15 PM
Hoerter Steven L.President and CEODec 13 '23Sale15.3730,664471,21772,763Dec 14 04:05 PM
Kelly Thomas PatrickChief Financial OfficerDec 13 '23Sale15.372,79242,90568,520Dec 14 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerDec 13 '23Sale15.372,79242,90596,514Dec 14 04:05 PM
Martin Daniel C.Chief Commercial OfficerDec 13 '23Sale15.371,72726,53949,284Dec 14 04:05 PM
Pitman JamaSee RemarksDec 13 '23Sale15.371,66225,54052,197Dec 14 04:05 PM
Martin Daniel C.Chief Commercial OfficerNov 30 '23Sale12.5717,801223,75545,435Dec 01 04:05 PM
Hoerter Steven L.President and CEOOct 30 '23Sale12.0221,573259,25640,927Oct 31 04:09 PM
Sherman Matthew LEVP & Chief Medical OfficerOct 30 '23Sale12.022,36028,36290,628Oct 31 04:11 PM
Kelly Thomas PatrickChief Financial OfficerOct 30 '23Sale12.022,31627,83363,068Oct 31 04:09 PM
Martin Daniel C.Chief Commercial OfficerOct 30 '23Sale12.021,40716,90962,884Oct 31 04:10 PM
Pitman JamaSee RemarksOct 30 '23Sale12.021,40716,90948,283Oct 31 04:10 PM
Sherman Matthew LEVP & Chief Medical OfficerOct 02 '23Sale12.682,94237,30584,744Oct 04 04:05 PM
Kelly Thomas PatrickChief Financial OfficerJun 16 '23Sale14.401,65523,83557,140Jun 21 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerJun 16 '23Sale14.401,65523,83587,686Jun 21 04:05 PM
Flynn Daniel LeeChief Scientific OfficerJun 16 '23Sale14.401,65523,83557,158Jun 21 04:05 PM
Martin Daniel C.Chief Commercial OfficerJun 16 '23Sale14.401,23817,82958,413Jun 21 04:05 PM
Pitman JamaSee RemarksJun 16 '23Sale14.401,23817,82943,812Jun 21 04:05 PM
Friedman Franklin StuartDirectorJun 08 '23Buy13.8810,000138,82810,000Jun 12 04:05 PM